29064-82-2Relevant articles and documents
NEW BICYCLIC DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page/Page column 111-112, (2017/05/12)
Compounds of formula (I); wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicaments.
Thienopyridine urea inhibitors of KDR kinase
Heyman, H. Robin,Frey, Robin R.,Bousquet, Peter F.,Cunha, George A.,Moskey, Maria D.,Ahmed, Asma A.,Soni, Niru B.,Marcotte, Patrick A.,Pease, Lori J.,Glaser, Keith B.,Yates, Melinda,Bouska, Jennifer J.,Albert, Daniel H.,Black-Schaefer, Candace L.,Dandliker, Peter J.,Stewart, Kent D.,Rafferty, Paul,Davidsen, Steven K.,Michaelides, Michael R.,Curtin, Michael L.
, p. 1246 - 1249 (2007/10/03)
A series of substituted thienopyridine ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 2, are potent inhibitors of KDR (10 nM) in both enzymatic and cellular assays. Further
Discovery of thienopyridines as Src-family selective Lck inhibitors
Abbott, Lily,Betschmann, Patrick,Burchat, Andrew,Calderwood, David J.,Davis, Heather,Hrnciar, Peter,Hirst, Gavin C.,Li, Biqin,Morytko, Michael,Mullen, Kelly,Yang, Bryant
, p. 1167 - 1171 (2007/10/03)
We describe the identification, SAR, and in vivo pharmacology of a new series of Src-family selective Lck inhibitors. These thienopyridines were designed based on a desire to access the unique residues in the extended hinge region of Lck.